| Name | Title | Contact Details |
|---|---|---|
Amar Murugan |
Senior Vice President and General Counsel | Profile |
Sarah Soifer |
Director, Compliance Counsel | Profile |
Mark Kresnak |
Assistant General Counsel of Intellectual Property | Profile |
Mina Kim |
General Counsel | Profile |
Mina Kim |
General Counsel | Profile |
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.
We`re on a mission to unlock molecular machines by understanding and respecting their complexities. We`ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines.
Levant Technologies is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Allergene is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ventana Clinical Research Corp is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.